ImmunityBio, Inc. (IBRX) Stock Analysis and Metrics

ImmunityBio

NASDAQ: IBRX

$7.08 ▼ -0.32 (-4.32%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap7.35 Bn

P/E-8.60

P/S52.11

Div. Yield0.00

Total Debt (Qtr)404.30 Mn

Revenue Growth (1y) (Qtr)167.64

Add ratio to table…

About

ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. The company harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. At the core of its strategy is the Cancer BioShield™ platform, which is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via its proprietary IL-15 superagonist, ANKTIVA® (nogapendekin alfa inbakicept).

ImmunityBio generates revenue primarily through the commercial sale of ANKTIVA, its approved biologic product for the treatment of BCG-unresponsive NMIBC CIS with or without papillary tumors. The company began commercial distribution of ANKTIVA in May 2024 following FDA approval and reported net product revenue of approximately $113 million for the full year 2025. Revenue is also supported by expanded access programs and potential future approvals for additional indications, including metastatic NSCLC and other solid and liquid tumor types.

The company operates through the following segments:

• Cytokine Fusion Proteins: This segment focuses on IL-15 receptor superagonist antibody-cytokine fusion proteins, with ANKTIVA as the lead product. ANKTIVA is a first-in-class IL-15 receptor superagonist that activates NK cells, CD8+ T cells, and memory T cells without expanding immunosuppressive Tregs. The segment also includes development of multi-functional cytokine fusion proteins targeting TGF-ß, PD-L1, CD16, CD20, and comprising IL-12, IL-15, and IL-21 to enhance immune responses in the tumor microenvironment.

• DNA and Vaccine Vectors: This segment utilizes adenovirus-vectored vaccines, including hAd5 constructs, to deliver tumor-associated antigens and neoepitopes for oncology and infectious diseases. Key product candidates target PSA, Brachyury, CEA, MUC1, HPV [E6/E7], and nucleocapsid antigens. These vectors are designed to induce B and T cell memory and antibody responses, with second-generation hAd5 [E1-, E2b-, E3-] vectors overcoming pre-existing adenovirus immunity.

• NK Cell Therapies: This segment includes off-the-shelf and autologous NK-cell therapies, such as the CAR NK Platform (CD19 CAR-NK or t-haNK, PD-L1 CAR-NK or t-haNK) and the Apheresis Platform (M-ceNK). M-ceNK cells are generated from donor lymphocytes pre-activated with IL-12, IL-15 (N-803), and IL-18 to enhance antitumor activity, persistence, and immune memory. The segment also includes haNK and taNK platforms for targeted cancer cell killing.

ImmunityBio holds a differentiated position in the immunotherapy industry through its Cancer BioShield platform, which integrates cytokine fusion proteins, vaccine vectors, and cell therapies to address lymphopenia and immune evasion in cancer. ANKTIVA is the only FDA-approved IL-15 receptor superagonist as of December 31, 2025, giving the company a first-mover advantage in this therapeutic class. The company competes with established therapies such as pembrolizumab (KEYTRUDA), nivolumab (OPDIVO), and atezolizumab (TECENTRIQ) in NSCLC, and with BCG and approved agents like nadofaragene firadenovec (ADSTILADRIN) and nadofaragene firadenovec-vncg in NMIBC, but distinguishes itself through its mechanism of activating both innate and adaptive immune systems without Treg expansion.

ImmunityBio serves hospitals, urology clinics, oncology centers, and infusion centers where its products are administered for the treatment of bladder cancer, lung cancer, pancreatic cancer, glioblastoma, lymphoma, and other solid tumors. The company’s ANKTIVA therapy is used in combination with BCG or checkpoint inhibitors in adult patients with BCG-unresponsive NMIBC CIS with or without papillary tumors and metastatic NSCLC progressing after standard-of-care therapy. Specific customer names are not disclosed in the filing, but the company reports payer coverage exceeding 240 million lives in the U. S. as of December 2025, supported by a permanent J-code (J9028) from CMS effective January 1, 2025.

Investment Thesis

▲ Bull case

ImmunityBio's patent portfolio covering the ANKTIVA plus BCG combination provides durable intellectual property protection through at least 2035, which safeguards its core bladder cancer franchise against generic competition and supports long-term pricing power; this is reinforced by the company's strategic partnership with Japan BCG Laboratory for the Tokyo-172 strain, which diversifies BCG supply and mitigates a critical industry-wide bottleneck that has historically constrained patient access and commercial growth, while the FDA's acceptance of the supplemental BLA for papillary-only disease expands the addressable market beyond the current CIS indication to include a larger segment of BCG-unresponsive patients, with NCCN already endorsing ANKTIVA plus BCG as a Category 2A option for this population, signaling strong clinical validation and impending reimbursement momentum.
The company's financial trajectory demonstrates explosive and sustainable top-line momentum, with Q1 2026 net product revenue reaching $44.2 million—a 168% year-over-year increase and 15% sequential growth from Q4 2025—building on full-year 2025 revenue of $113.0 million, which represented a 700% surge over 2024, driven by accelerating physician adoption, expanding global regulatory approvals across 34 countries, and successful commercial execution in key markets like Saudi Arabia and Macau; this growth is further underpinned by $380.9 million in cash and marketable securities as of March 31, 2026, providing ample runway to fund operations and pipeline advancement without immediate dilution risk, while the $75 million incremental non-dilutive financing from Oberland Capital increases total committed capital under the RIPA to $375 million, strengthening the balance sheet and enabling continued scaling of commercial efforts and global expansion following recent approvals.
ImmunityBio's clinical pipeline is advancing with de-risked catalysts, including the fully enrolled QUILT-2.005 trial in BCG-naïve NMIBC, where the Independent Data Monitoring Committee confirmed adequate statistical power to detect a clinically meaningful difference in complete response rate between ANKTIVA plus BCG and BCG alone, eliminating the need for further enrollment and positioning the company for a supplemental BLA submission in Q4 2026; this is complemented by compelling real-world evidence from health economic analyses showing ANKTIVA plus BCG achieves a lower cost per sustained complete responder than TAR-200 in Medicare populations, driven by superior durability of response (49.6% vs. 45.9% CR rate) and lower drug acquisition costs, which enhances reimbursement prospects and positions the therapy as a cost-effective standard of care, while ongoing ASCO and AUA presentations continue to generate physician-level validation and awareness across multiple tumor indications, including NSCLC and bladder cancer, reinforcing the broader applicability of the IL-15 platform beyond current approvals.

ImmunityBio's patent portfolio covering the ANKTIVA plus BCG combination provides durable intellectual property protection through at least 2035, which safeguards its core bladder cancer franchise against generic competition and supports long-term pricing power; this is reinforced by the company's strategic partnership with Japan BCG Laboratory for the Tokyo-172 strain, which diversifies BCG supply and mitigates a critical industry-wide bottleneck that has historically constrained patient access and commercial growth, while the FDA's acceptance of the supplemental BLA for papillary-only disease expands the addressable market beyond the current CIS indication to include a larger segment of BCG-unresponsive patients, with NCCN already endorsing ANKTIVA plus BCG as a Category 2A option for this population, signaling strong clinical validation and impending reimbursement momentum.
The company's financial trajectory demonstrates explosive and sustainable top-line momentum, with Q1 2026 net product revenue reaching $44.2 million—a 168% year-over-year increase and 15% sequential growth from Q4 2025—building on full-year 2025 revenue of $113.0 million, which represented a 700% surge over 2024, driven by accelerating physician adoption, expanding global regulatory approvals across 34 countries, and successful commercial execution in key markets like Saudi Arabia and Macau; this growth is further underpinned by $380.9 million in cash and marketable securities as of March 31, 2026, providing ample runway to fund operations and pipeline advancement without immediate dilution risk, while the $75 million incremental non-dilutive financing from Oberland Capital increases total committed capital under the RIPA to $375 million, strengthening the balance sheet and enabling continued scaling of commercial efforts and global expansion following recent approvals.
ImmunityBio's clinical pipeline is advancing with de-risked catalysts, including the fully enrolled QUILT-2.005 trial in BCG-naïve NMIBC, where the Independent Data Monitoring Committee confirmed adequate statistical power to detect a clinically meaningful difference in complete response rate between ANKTIVA plus BCG and BCG alone, eliminating the need for further enrollment and positioning the company for a supplemental BLA submission in Q4 2026; this is complemented by compelling real-world evidence from health economic analyses showing ANKTIVA plus BCG achieves a lower cost per sustained complete responder than TAR-200 in Medicare populations, driven by superior durability of response (49.6% vs. 45.9% CR rate) and lower drug acquisition costs, which enhances reimbursement prospects and positions the therapy as a cost-effective standard of care, while ongoing ASCO and AUA presentations continue to generate physician-level validation and awareness across multiple tumor indications, including NSCLC and bladder cancer, reinforcing the broader applicability of the IL-15 platform beyond current approvals.

▼ Bear case

ImmunityBio faces significant regulatory and reputational headwinds stemming from the FDA's warning letter regarding false or misleading promotional claims about ANKTIVA's efficacy, which alleges the company overstated the drug's capabilities to treat 'all cancers' and function as a cancer vaccine despite clinical data being limited to a single-arm trial of only 77 patients with a 62% complete response rate and no interpretable disease-free survival data; this led to a 21-26% single-day stock decline and has triggered securities class action lawsuits with a lead plaintiff deadline of May 26, 2026, creating overhang from potential settlements, legal expenses, and ongoing scrutiny that could impair investor confidence and limit future promotional flexibility, even as the company has taken corrective actions, the underlying issue of overpromising relative to clinical evidence remains a structural risk to long-term credibility.
The company's financials are distorted by significant non-cash volatility driven by its complex capital structure, as evidenced by Q1 2026 GAAP net loss of $632.8 million—largely fueled by a $530.9 million non-cash charge from changes in fair value of warrant and derivative liabilities and a related-party convertible note due to rising stock price—while adjusted net loss was only $86.2 million, highlighting a major divergence between GAAP results and underlying operational performance; this accounting complexity obscures true profitability trends, creates unnecessary volatility in earnings, and raises concerns about the sustainability of its financing model, particularly given the $678.4 million related-party convertible note payable at fair value and $404.3 million revenue interest liability on the balance sheet as of March 31, 2026, which together exceed total assets and contribute to a substantial stockholders' deficit of $870.0 million.
Despite progress in regulatory approvals and supply chain diversification, ImmunityBio remains heavily dependent on the success of its ANKTIVA plus BCG franchise, with near-term catalysts like the sBLA for papillary-only disease (PDUFA date January 6, 2027) and QUILT-2.005 data readout carrying binary risk—if the FDA requires additional data, rejects the extrapolation rationale between CIS and papillary disease, or fails to confirm clinically meaningful superiority over BCG alone in the BCG-naïve setting, the company's growth narrative could unravel rapidly; furthermore, ongoing BCG supply constraints, while mitigated by the Tokyo-172 and rBCG partnerships, are not yet resolved, as both products remain investigational in the U.S., and any delay in FDA approval of Tokyo-172 BCG or scalability issues with rBCG could constrain commercial expansion, especially given the company's reliance on bladder cancer indications for the vast majority of its current revenue, with limited diversification into other oncology areas like NSCLC still in early-stage development.

ImmunityBio faces significant regulatory and reputational headwinds stemming from the FDA's warning letter regarding false or misleading promotional claims about ANKTIVA's efficacy, which alleges the company overstated the drug's capabilities to treat 'all cancers' and function as a cancer vaccine despite clinical data being limited to a single-arm trial of only 77 patients with a 62% complete response rate and no interpretable disease-free survival data; this led to a 21-26% single-day stock decline and has triggered securities class action lawsuits with a lead plaintiff deadline of May 26, 2026, creating overhang from potential settlements, legal expenses, and ongoing scrutiny that could impair investor confidence and limit future promotional flexibility, even as the company has taken corrective actions, the underlying issue of overpromising relative to clinical evidence remains a structural risk to long-term credibility.
The company's financials are distorted by significant non-cash volatility driven by its complex capital structure, as evidenced by Q1 2026 GAAP net loss of $632.8 million—largely fueled by a $530.9 million non-cash charge from changes in fair value of warrant and derivative liabilities and a related-party convertible note due to rising stock price—while adjusted net loss was only $86.2 million, highlighting a major divergence between GAAP results and underlying operational performance; this accounting complexity obscures true profitability trends, creates unnecessary volatility in earnings, and raises concerns about the sustainability of its financing model, particularly given the $678.4 million related-party convertible note payable at fair value and $404.3 million revenue interest liability on the balance sheet as of March 31, 2026, which together exceed total assets and contribute to a substantial stockholders' deficit of $870.0 million.
Despite progress in regulatory approvals and supply chain diversification, ImmunityBio remains heavily dependent on the success of its ANKTIVA plus BCG franchise, with near-term catalysts like the sBLA for papillary-only disease (PDUFA date January 6, 2027) and QUILT-2.005 data readout carrying binary risk—if the FDA requires additional data, rejects the extrapolation rationale between CIS and papillary disease, or fails to confirm clinically meaningful superiority over BCG alone in the BCG-naïve setting, the company's growth narrative could unravel rapidly; furthermore, ongoing BCG supply constraints, while mitigated by the Tokyo-172 and rBCG partnerships, are not yet resolved, as both products remain investigational in the U.S., and any delay in FDA approval of Tokyo-172 BCG or scalability issues with rBCG could constrain commercial expansion, especially given the company's reliance on bladder cancer indications for the vast majority of its current revenue, with limited diversification into other oncology areas like NSCLC still in early-stage development.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password